Given its stromal localization, targeting COL4A6 with antibody-drug conjugates (ADCs) or other therapeutic strategies may offer a novel approach to overcoming chemoresistance, as has been explored in pancreatic cancer [54]. The gene discussed is COL4A6; the disease is familial pancreatic carcinoma.